HEPTARES
LIVE

Serial Number

86577541

Owner

Heptares Therapeutics Limited

Attorney

Rebecca Liebowitz

Filing Date

Mar 26, 2015

Add to watchlist:

No watchlists yet
View on USPTO

HEPTARES Trademark

Serial Number: 86577541 • Registration: 5239010

HEPTARES is a trademark filed by Heptares Therapeutics Limited on March 26, 2015. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific), Class 44 (Medical Services). The application is currently registered and active.

Owner Contact Info

Heptares Therapeutics Limited (4 trademarks)

Steinmetz Building
Cambridge CB21 6DG , GB

Entity Type: 99

NXERA PHARMA CO., LTD

9-7-2 AKASAKA MINATO-KU
TOKYO 107-0052 , JP

Entity Type: 99

SOSEI GROUP CORPORATION

CHIYODA-KU
TOKYO 102-0083 , JP

Entity Type: 03

Trademark Details

Filing Date

March 26, 2015

Registration Date

July 11, 2017

Published for Opposition

April 25, 2017

Goods & Services

Biotechnology testing, namely, genetic testing for scientific research purposes; Biotechnology research; Biotechnology development, namely, development in the field of drug discovery and biopharmaceuticals; biotechnology advice; Biotechnology consultancy; Biotechnology information, namely, providing information on the subject of scientific research in the field of biotechnology; Pharmaceutical testing; pharmaceutical research; pharmaceutical development; pharmaceutical consultancy for non-medical purposes; Providing medical and scientific research information in the fields of pharmaceuticals; scientific testing and research in the pharmaceutical and biopharmaceutical fields, namely, chemical and biological drug discovery services; providing scientific information, advice, and consultancy in the field of technologies related to proteins, including transmembrane proteins and G-proteins, and G protein coupled receptors, and parts thereof; bio-technology, pharmaceutical and scientific testing, research, development, advice, consultancy and information services; biological research; Research and development in the pharmaceutical and biopharmaceutical fields, namely, technologies related to proteins and G protein coupled receptors; biology and chemistry services, namely, research and consulting in the field of chemistry and biology; pharmaceutical research services, namely, chemical and biological drug discovery services; research and development services for pharmaceutical lead identification; synthetic chemistry consultation services and research; research and development services in the creation of libraries or collections of biologicals, chemicals and compounds; research, creation, development and provision of chemical and biological drug targets for non-medical screening purposes; research, analysis and identification of compounds through automated screening processes research and development services relating to pharmaceutical research services, namely, chemical and biological drug discovery services

Pharmaceutical advice; pharmaceutical consultancy for medical purposes; providing information relating to diagnostic, prophylactic and therapeutic properties of pharmaceuticals; research, creation, development and provision of chemical and biological drug targets for medical screening purposes

[ Biological products for medical purposes, namely, g-protein-coupled receptors, transmembrane proteins and parts thereof for use in chemical and biological drug discovery, lead identification, diagnostics and therapeutic purposes; biological and chemical products for medical use, namely, proteins, G-protein-coupled receptors, transmembrane proteins, G-Proteins, antibodies and peptides and parts thereof, for therapeutic purposes; chemicals, proteins and parts thereof for use in medical diagnostics; none being dietetic substances adapted for medical use or food products ]

[ Chemicals and proteins used in research, namely, for chemistry and biological drug discovery, lead identification and diagnostics; proteins including G-protein-coupled receptors, trans-membrane proteins and parts thereof, for use in pharmaceutical research, namely, drug discovery purposes ]

Filing History

COURTESY REMINDER - SEC. 8 (10-YR)/SEC. 9 E-MAILED
Jul 11, 2026 REM2
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
Jul 4, 2024 ASGN
NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED
Jan 2, 2024 NA85
REGISTERED - PARTIAL SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.
Jan 2, 2024 C15P
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Jan 2, 2024 APRE
TEAS SECTION 8 & 15 RECEIVED
Jul 10, 2023 E815
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
Jul 11, 2022 REM1
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
May 6, 2020 ASGN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Oct 30, 2018 CHAN
TEAS CHANGE OF OWNER ADDRESS RECEIVED
Oct 30, 2018 COAR
REGISTERED-PRINCIPAL REGISTER
Jul 11, 2017 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Apr 25, 2017 NPUB
PUBLISHED FOR OPPOSITION
Apr 25, 2017 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Apr 5, 2017 NONP
LAW OFFICE PUBLICATION REVIEW COMPLETED
Mar 17, 2017 PREV
APPROVED FOR PUB - PRINCIPAL REGISTER
Mar 10, 2017 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Feb 3, 2017 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Feb 3, 2017 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Feb 1, 2017 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Aug 5, 2016 GNRN
NON-FINAL ACTION E-MAILED
Aug 5, 2016 GNRT
NON-FINAL ACTION WRITTEN
Aug 5, 2016 CNRT
NOTIFICATION OF SUBSEQUENT FINAL EMAILED
Jul 7, 2016 GNS1
SUBSEQUENT FINAL EMAILED
Jul 7, 2016 GNSF
SUBSEQUENT FINAL REFUSAL WRITTEN
Jul 7, 2016 CFRC
TEAS/EMAIL CORRESPONDENCE ENTERED
Jun 15, 2016 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jun 15, 2016 CRFA
TEAS REQUEST FOR RECONSIDERATION RECEIVED
Jun 15, 2016 ERFR
NOTIFICATION OF FINAL REFUSAL EMAILED
Mar 8, 2016 GNFN
FINAL REFUSAL E-MAILED
Mar 8, 2016 GNFR
FINAL REFUSAL WRITTEN
Mar 8, 2016 CNFR
TEAS/EMAIL CORRESPONDENCE ENTERED
Feb 16, 2016 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Feb 16, 2016 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Feb 16, 2016 TROA
NOTIFICATION OF NOTICE OF UNRESPONSIVE AMENDMENT - E-MAILED
Jan 20, 2016 GAUN
NOTICE OF UNRESPONSIVE AMENDMENT - E-MAILED
Jan 20, 2016 GAUD
REPORT UNRESPONSIVE AMENDMENT - COMPLETED
Jan 20, 2016 NAUD
TEAS/EMAIL CORRESPONDENCE ENTERED
Jan 20, 2016 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jan 20, 2016 CRFA
ASSIGNED TO LIE
Jan 15, 2016 ALIE
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jan 8, 2016 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Jul 12, 2015 GNRN
NON-FINAL ACTION E-MAILED
Jul 12, 2015 GNRT
NON-FINAL ACTION WRITTEN
Jul 12, 2015 CNRT
ASSIGNED TO EXAMINER
Jun 29, 2015 DOCK
PRELIMINARY/VOLUNTARY AMENDMENT - ENTERED
Jun 5, 2015 AMPX
ASSIGNED TO LIE
Jun 1, 2015 ALIE
TEAS VOLUNTARY AMENDMENT RECEIVED
May 27, 2015 PARI
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Apr 4, 2015 NWOS
NEW APPLICATION ENTERED
Mar 30, 2015 NWAP